Benjamin Landman is a child psychiatrist. He is chief resident at the Excellence Center for Autism and Neurodevelopmental Disorders at the Robert Debré Hospital, in Paris, France. He has a major interest in the identification of biomarkers in autism. He is mainly involved in the project SoNeTAA (Social Neuroscience for Therapeutic Approaches in Autism) and combines human-human and human-machine interactions with electroencephalography recording to study social cognition from a situated and reciprocal standpoint. The project aims to bridge the gap between state-of-the-art social neuroscience methods and clinical practices. He is also co-founder of the www.debrechildpsychiatry.org website.
Benjamin Landman
Chief resident
Center of Excellence for Autism Spectrum Disorders and Neurodevelopmental Disorders
From this contributor
Coronavirus tool kit may aid families with autistic children during lockdown
To help families cope with the sudden loss of professional support during the pandemic, one team in France has created a set of resources and information.
Coronavirus tool kit may aid families with autistic children during lockdown
Explore more from The Transmitter
Exclusive: Brain and spinal cord institute halts research, citing funding problems
The Burke Neurological Institute, which calls itself “the only research institute in the U.S. dedicated to finding treatments to repair the brain and spinal cord,” ceased research operations on 22 May.
Exclusive: Brain and spinal cord institute halts research, citing funding problems
The Burke Neurological Institute, which calls itself “the only research institute in the U.S. dedicated to finding treatments to repair the brain and spinal cord,” ceased research operations on 22 May.
When autistic kids grow up, Chapter 1: Those people
What leads an autism researcher to publish an intentionally inflammatory paper accusing the NIH of discrimination?
When autistic kids grow up, Chapter 1: Those people
What leads an autism researcher to publish an intentionally inflammatory paper accusing the NIH of discrimination?
Supported by a $40 million NIH grant, Yale brain shuttle technology raises questions
Yale University claims its STEP platform might be able to deliver gene-editing tools into the brain via multiple routes. Researchers are eager to see more.
Supported by a $40 million NIH grant, Yale brain shuttle technology raises questions
Yale University claims its STEP platform might be able to deliver gene-editing tools into the brain via multiple routes. Researchers are eager to see more.